FDA To Companion Dx Developers: Pre-Trial Assay Validation Is Key
This article was originally published in The Gray Sheet
Executive Summary
Companion diagnostic device makers should ensure their test is analytically validated prior to its use in a drug pivotal trial, FDA stressed at a Sept. 26 meeting at the University of Virginia in Charlottesville.